#United States #New York #Class Action #Pomerantz LLP #Gossamer Bio

Investor Alert from Pomerantz Law Firm

On May 21, 2026, the Pomerantz Law Firm announced the filing of a class action lawsuit against Gossamer Bio, Inc. (NASDAQ: GOSS). This lawsuit is directly related to substantial investment losses incurred by shareholders of Gossamer. Investors are encouraged to reach out to Pomerantz’s Danielle Peyton either by email or phone for further details, especially if they had purchased Gossamer securities during the class period.

The crux of the class action revolves around allegations of securities fraud and unlawful business practices by Gossamer and some of its executives. This initiative grants affected investors until June 1, 2026, to file a lead plaintiff motion in court. Interested individuals can find a copy of the complaint on the Pomerantz website.

Gossamer's Troubling Recent Performance

A pivotal moment for Gossamer occurred on February 23, 2026, when the company publicly disclosed the results of its Phase 3 PROSERA study, which evaluated seralutinib as a treatment for pulmonary arterial hypertension. Unfortunately, the study fell short of meeting its primary endpoint, specifically in terms of the six-minute walk distance at Week 24. The company reported a placebo-adjusted gain of only +13.3 meters, which did not meet the required alpha threshold of 0.025.

This disappointing news was reflected in Gossamer's stock price, which plummeted by $1.71, marking an 80.13% decline and closing at only $0.42 per share. Gossamer indicated that this decline might have been influenced by the performance of patients in Latin American sites, who demonstrated unexpectedly favorable outcomes with placebo due to the inclusion of a heavily treated, lower-risk patient cohort.

Overview of Pomerantz Law Firm

Pomerantz LLP, a prominent law firm with a rich history and offices in major cities such as New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is well-regarded for its work in corporate, securities, and antitrust class litigation. Founded over 85 years ago by Abraham L. Pomerantz, a pioneer in the securities class action field, the firm has established a legacy of fighting for the rights of investors and the recovery of damages in cases of securities fraud and corporate wrongdoing.

As a collective that has secured numerous multimillion-dollar settlements for class members, Pomerantz LLP continues to operate by the ethical standards and fighting spirit set forth by its founder. For further information on how to join or inquire about the class action against Gossamer Bio, prospective plaintiffs can visit Pomerantz Law Firm's website.

Contact Information

For inquiries related to this class action, investors can contact:
Danielle Peyton
Email: [email protected]
Phone: 646-581-9980, Ext. 7980 (toll-free: 888.4-POMLAW)

Stay informed, as this development could significantly impact those involved in investment dealings with Gossamer Bio.